DSM establishes CEPs and US Drug Master Files for 13 essential vitamins

Published: 7-Oct-2016
Ingredients Regulatory

DSM has received the US Drug Master Files (DMFs) for all 13 essential vitamins, making it the first company worldwide to hold both the US DMFs and CEPs for this active pharmaceutical ingredient (API) portfolio


This means DSM can offer its pharmaceutical customers worldwide a competitive edge by accelerating the registration process to get products to market faster.

Kristina Cselovszky, Business Development Director Pharma at DSM Nutritional Products, states: 'In a highly regulated and competitive market, our customers need bespoke solutions to stay ahead of their competition. As the only company holding US DMFs and CEPs for these 13 essential vitamins, we offer quicker and easier pharma registrations. Our ICH Q7-compliant production sites ensure we provide customers with safe, high-quality products.'

With extensive experience in vitamin and EPA and DHA active pharmaceutical ingredients (APIs), DSM is in a unique position to provide customers with entirely customised support throughout every stage of a project from initial conception.

In addition to its strong API portfolio, including vitamins, carotenoids, DHA, EPA and statins (by DSM Sinochem Pharmaceuticals), DSM’s 400-strong R&D team provides expertise in clinical trials.

DSM also has a global network of regulatory specialists, equipped to support customers’ local pharma product registrations. Offering an unparalleled reliability of supply and speed to market, DSM’s full regulatory, scientific and quality expertise ensures that projects are both safe and compliant.

  • Companies:
  • dsm-firmenich
See more

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

Read more
The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. Rousselot Biomedical launches EU MDR compliant gelatin range From May 2024, all devices placed on the European market must conform with the EU Medical Device Regulation (MDR)

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
Ingredients

Humanetics acquires all legal assets of DSM radioprotective API

All patents, trademarks, trade secret manufacturing processes of the API for BIO 300 have been sold to US-based Humanetics
Ingredients

DSM at CPhI: the rapidly evolving role of vitamins and lipids in disease management

Royal DSM, a global science-based company active in nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2018
Subscribe now